Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02400437 · OUTCOME

Overall Response Rate by MYD88 L265P and CXCR4-WHIM Status

Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia · Source last updated 2020-09-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
2 Years

What was measured

To evaluate the overall response rate of participants by MYD88 L265P and CXCR4-WHIM mutations in WM. Overall response is defined as achieving at least a minor response, or \>25% reduction in serum IgM from baseline.

Analysis population: Number of participants who achieved a response by mutational status

Groups in this outcome

MYD88 Mutated, CXCR4 Wild-type

Participants who were MYD88 mutated and did not have the CXCR4 mutation

MYD88 Mutated, CXCR4 Mutated

Participants with both the MYD88 mutation and a CXCR4 mutation

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
MYD88 Mutated, CXCR4 Wild-type11
MYD88 Mutated, CXCR4 Mutated15

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
MYD88 Mutated, CXCR4 Wild-type11Not reportedNot reportedNot reportedNot reported
MYD88 Mutated, CXCR4 Mutated14Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        11
      2. group Id
        OG001
        value
        14
denoms
  1. counts
    1. group Id
      OG000
      value
      11
    2. group Id
      OG001
      value
      15
    units
    Participants
description
To evaluate the overall response rate of participants by MYD88 L265P and CXCR4-WHIM mutations in WM. Overall response is defined as achieving at least a minor response, or \>25% reduction in serum IgM from baseline.
groups
  1. description
    Participants who were MYD88 mutated and did not have the CXCR4 mutation
    id
    OG000
    title
    MYD88 Mutated, CXCR4 Wild-type
  2. description
    Participants with both the MYD88 mutation and a CXCR4 mutation
    id
    OG001
    title
    MYD88 Mutated, CXCR4 Mutated
param Type
COUNT_OF_PARTICIPANTS
population Description
Number of participants who achieved a response by mutational status
reporting Status
POSTED
time Frame
2 Years
title
Overall Response Rate by MYD88 L265P and CXCR4-WHIM Status
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice